CMIRPS 

Canadian Medication Incident Reporting and Prevention System

A collaborative pan-Canadian program of Health Canada, the Canadian Institute for Health Information (CIHI), the Institute for Safe Medication Practices Canada (ISMP) and the Canadian Patient Safety Institute (CPSI). The goal of CMIRPS is to reduce and prevent harmful medication incidents in Canada.

CIHI

Canadian Institute of Health Information 

A web tool for the health sector and the general public. It provides comparable, interactive data so that hospitals, regions, provinces and territories can compare how they measure up on 37 indicators related to access, quality of care, patient safety & emerging health trends across the country. CIHI produces analytic reports from NSIR data and makes them publicly available.

NSIR (software)

National System for Incident Reporting

A web-based application to securely and anonymously share, analyze and discuss medication incidents & operated by the Canadian Institute of Health Information (CIHI).

ISMP 

Institute for Safe Medication Practices Canada

An independent national organization committed to the advancement of medication safety. It works with the healthcare community to promote safe medication practices & making recommendations for the prevention of harmful medication incidents.

CPhIR

The Community Pharmacy Incident Reporting (Designed by ISMP Canada, announced 12 September 2014)

This program provides community-based pharmacies with a secure, one-stop, online location to anonymously report and analyze medication incidents; export data for customized analysis; and view comparisons of individual pharmacy and national aggregate data.

CPSI 

Canadian Patient Safety Institute

Works with governments, health organizations, leaders, and healthcare providers to raise awareness and facilitate the implementation of ideas and best practices to achieve a transformation in patient safety. They envision safe healthcare for all Canadians and are driven to inspire extraordinary improvement in patient safety and quality. 

Canada Vigilance Program (MedEffect™) 

Post-market surveillance program that collects and assesses reports of suspected adverse drug reactions marketed in Canada. Adverse drug reaction reports should be submitted to the Canada Vigilance Program operated by Health Canada.

DPD

Drug Product Database

A database that contains product-specific information on drugs approved for use in Canada. The database is managed by Health Canada and includes human pharmaceutical and biological drugs, veterinary drugs and disinfectant products.

CHA

Canada Health Act

Federal legislation puts in place conditions by which provinces & territories in Canada may receive funding for health care services.

There are 5 main principles in the Canada Health Act (PUPAC)

• Public Administration
• Universality
• Portability
• Accessibility
• Comprehensiveness

 (All EXCEPT Affordability)

CADTH

Canadian Agency for Drugs and Technologies in Health

Independent, non-profit, funded by Federal, Provincial and Territorial.

Provides decision-makers with the evidence, analysis and advice about the effectiveness of drug and devices, and recommendations they require to make decisions (approval) of drug registration in health care. CADTH has 3 programs:

1. HTA Health Technology Assessment - Assessment of drug, health technology.
2. CDR Common Drug Review - A conducting reviews of the clinical, cost-effectiveness, and patient evidence for drugs and providing a formulary listing recommendation.
3. COMPUS - Canadian Optimal Medicine Prescribing and Utilization Services. Identifying and promoting the optimal drug use through pharmacists (Academic Detailing or Pharmacist Physician Detailing or Counter Detailing) → Canadian Academic Detailing Collaboration (CADC) → improvements observed in physician prescribing of Ab, BDZs, and NSAIDs

NOC

Notice of Compliance

This is issued to a manufacturer following the satisfactory review of a submission for a new drug and signifies compliance with the Food & Drug Regulations, it allows the drug to be released to the market.

PIPEDA

Personal Information Protection and Electronic Documents Act

Supports and promotes electronic commerce by protecting personal information that is collected, used or disclosed in certain circumstances.

PHIPA

Personal Health Information Protection Act

Assures confidentiality of patients' information.

RHPA

Registered Health Professional Act

Do not date patients from your pharmacy and fill their Rx (even your spouse).

HPB

Health Protection Branch 

Responsible for Drug Quality, Safety and Efficacy.

Imported and Manufactured drugs sold in Canada.

MHPD

Marketed Health Products Directorate

Monitors the safety, effectiveness, and quality of marketed health products in Canada.

HPFB

Health Products & Food Branch

Responsible for post-market surveillance of marketed health products.

Sub-branches are SAP & TPD.

SAP

The Special Access Programme 

Provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable (a quantity of 6 months or less).

TPD

Therapeutic Products Directorate

The federal authority that regulates Rx, non-Rx products and medical devices for human use in Canada. 

NPHD

Natural Health Products Directorate

• Regulates natural health products, vitamins/mineral supplements & herbal products
• Assigns NPN for each natural product approved for market

PMPRB

Patented Medicines Prices Review Board

Controls the price of brands (not generics)

DSMB

Data Safety Monitoring Board

• Reviews data while a clinical trial is in progress
• May recommend that a trial is stopped for safety concerns